Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
EVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.84 - $5.68
Previous CloseN/A
Volume32.72K
Average Volume (3M)117.68K
Market Cap
$1.49B
Enterprise Value$1.48B
Total Cash (Recent Filing)€24.84M
Total Debt (Recent Filing)€13.00M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding355,527,040
10 Day Avg. Volume134,057
30 Day Avg. Volume117,677
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.46
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.50Price Target Upside77.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Evotec AG News
PremiumCompany Announcements
Evotec SE Reports Strong Q4 2024 and New Strategy
PremiumCompany Announcements
Evotec Ag’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Evotec SE Announces CFO Transition to Drive Strategic Growth
PremiumCompany Announcements
Evotec SE Announces Strong Q4 2024 Results and New Strategic Focus
---
Bulls Say, Bears Say
Bulls Say
CollaborationsAn extension of collaboration with Bristol Myers Squibb on targeted protein degradation into indications outside of oncology triggered $50M payment.
Cost EfficiencyThe company completed the first two steps by closing multiple sites to improve cost efficacy, which delivered annualized recurring gross savings of €40M, and completed the strategic review to 'rebuild' the business model.
Revenue GrowthGuidance of 5-10% revenue growth in 2025 is encouraging.
Bears Say
Facility InvestmentsOngoing investments to bring the Toulouse facility fully online will likely offset some of the gains from JEB growth.
Macroeconomic HeadwindsUnderwhelming Q3 revs of €184.9M driven by shared R&D still seeing macro headwinds.
R&D RevenuesPharma funding uncertainties impacted demand, resulting in lighter Shared R&D revenues.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.37% Other Institutional Investors
98.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.84 and its highest was $5.68 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.49B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is May 06, 2025 which is in 9 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is >-0.01.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,527,040 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
---
Evotec AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (77.73% Upside)
$7.50 (77.73% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 11.1%
Last 30 Days ▼ 11.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.25%
12-Months-Change
Fundamentals
Return on Equity
-19.05%
Trailing 12-Months
Asset Growth
-18.59%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
---
EVO Company Deck
---
EVO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive elements such as strong Q4 performance, significant growth in Just-Evotec Biologics, and successful partnerships, balanced against challenges like declining Shared R&D revenue and a high fixed cost base in a challenging market environment.Read More>---
EVO Stock 12 Month Forecast
Average Price Target
$7.50
▲(77.73% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Harrow Health
―
Best Analysts Covering EVO
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-24.02%
reiterated a buy rating 6 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -24.02% per trade.
---